Table 2. Unadjusted pooled adverse event rates occurring in patients with versus without permanent dual antiplatelet therapy discontinuation.

Variable		No permanent discontinuation	Permanent discontinuation*	HR (95% CI) for no permanent discontinuation	p-value¶
Myocardial infarction	0-1 year	4.8% (117/2,472)	6.6% (33/498)	0.61 (0.41-0.91)	0.08
	1-3 years	5.2% (71/1,431)	2.1% (31/1,480)	2.33 (1.49-3.57)	<0.0001
	0-3 years	10.9% (157/1,493)	5.6% (81/1,477)	1.85 (1.39-2.44)	<0.0001
Scaffold thrombosis	0-1 year	1.1% (27/2,481)	1.9% (9/489)	0.47 (0.21-1.05)	0.17
	1-3 years	1.4% (18/1,427)	0.9% (13/1,484)	1.56 (0.76-3.23)	0.28
	0-3 years	2.8% (40/1,475)	1.9% (27/1,495)	1.49 (0.91-2.44)	0.08
Bleeding	0-1 year	0.8% (20/2,491)	0.6% (3/479)	0.69 (0.20-2.38)	0.68
	1-3 years	1.2% (17/1,443)	0.6% (9/1,468)	1.43 (0.63-3.23)	0.09
	0-3 years	2.1% (30/1,491)	1.3% (19/1,479)	1.15 (0.64-2.04)	0.09
Death	0-1 year	0.8% (19/2,487)	1.2% (6/483)	0.56 (0.21-1.47)	0.30
	1-3 years	3.4% (46/1,447)	0.8% (11/1,464)	4.55 (2.27-8.33)	<0.0001
	0-3 years	3.6% (51/1,482)	2.2% (31/1,488)	1.61 (1.02-2.56)	0.02
Note: 16.2% of patients had permanent dual antiplatelet therapy (DAPT) discontinuation between 0 and 1 year, and 50.7% of patients had permanent DAPT discontinuation between 1 and 3 years. *≥2 days and until last follow-up or time of event. ¶p-values by log-rank test and hazard ratios by Cox regression. CI: confidence interval; HR: hazard ratio